Estrogen protects female mice with chronic kidney disease from fibroblast growth factor 23-induced left ventricular hypertrophy
Listen to this summary
The authors investigate how estrogen influences cardiac responses to fibroblast growth factor 23 (FGF23) in female mice with chronic kidney disease (CKD), particularly in relation to left ventricular hypertrophy (LVH). Their findings reveal that estrogen protects female mice from FGF23-induced LVH, highlighting sex-specific differences in cardiovascular risk and the potential molecular mechanisms involved. This study underscores the cardioprotective role of estrogen in females with CKD and identifies common signaling pathways between FGF23 and estrogen in the heart.
This is one of 33,000+ journals available on OSLR. Try it free for 14 days.
Free 14-day trial. 33,000+ journals. Cancel anytime.

More from Kidney international
View all →Apr 30, 2026 · Kidney international
Advances in survival analyses: machine learning methods and model comparison
Apr 29, 2026 · Kidney international
A MEF2C transcription factor network regulates proliferation of glomerular endothelial cells in diabetic kidney disease
Apr 29, 2026 · Kidney international
Insights from the BLISS-LN Phase 3 study of biomarker associations with kidney response to belimumab in lupus nephritis
Apr 27, 2026 · Kidney international
The calcimimetic etelcalcetide restores cardiac function in chronic hyperphosphatemia via calcium sensing receptor-cAMP activation
Apr 26, 2026 · Kidney international
Reversal of advanced diabetic kidney disease in mice treated with a monoclonal anti-VEGFR1 antibody
Apr 25, 2026 · Kidney international
Clinical and Histologic Predictors of Non-Diabetic Kidney Disease in Patients with Diabetes Mellitus
More in Internal Medicine
View all →May 10, 2026 · JAMA
Digoxin in Patients With Symptomatic Rheumatic Heart Disease: A Randomized Clinical Trial
May 10, 2026 · European heart journal
Blinded withdrawal of randomized treatment with low-dose digoxin or placebo in patients with heart failure: the DECISION trial
May 10, 2026 · Lancet (London, England)
Endovascular thrombectomy for patients with large-core ischaemic stroke presenting up to 24 h after onset (ATLAS): a systematic review and individual patient data meta-analysis with central imaging adjudication
May 10, 2026 · European heart journal
Renin-angiotensin-aldosterone system inhibition and haemocompatibility-related adverse events in patients with durable left ventricular assist device: the MOMENTUM-3 trial
May 10, 2026 · JAMA
Efficacy and Safety of Digitalis Glycosides in Heart Failure: A Meta-Analysis
May 10, 2026 · Lancet (London, England)
Impact of introducing RTS,S/AS01<sub>E</sub> malaria vaccine on mortality in young children in Ghana, Kenya, and Malawi: an observational evaluation of a cluster-randomised implementation programme
"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."
Dr. Jennifer Thompson
Portland, OR


